SCHEDULE: Katzman Discloses 5.16% Stake in TransCode Therapeutics

Daniel Eduardo Katzman has reported beneficial ownership of 155,611 shares, representing 5.16% of the outstanding common stock of TransCode Therapeutics, Inc.

Summary

• Daniel Eduardo Katzman has filed a Schedule 13G, indicating beneficial ownership of 155,611 shares of TransCode Therapeutics, Inc. common stock.
• This holding represents 5.16% of the company's outstanding common stock.
• Katzman possesses sole voting power and sole dispositive power over these shares.
• The filing date for this statement is July 28, 2026, with the event date being July 23, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain operational or financial performance information.

Positives

• Significant individual ownership stake of 5.16% reported by Daniel Eduardo Katzman.
• Clear disclosure of sole voting and dispositive power over the reported shares.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant beneficial ownership, indicating an investor's stake in a publicly traded company. This filing by Daniel Eduardo Katzman provides transparency regarding his holdings in TransCode Therapeutics.

Stakeholder Impact

• Shareholders: Provides transparency on a significant individual shareholder's stake, which can be a factor in market perception.

Key Dates

Keywords

TransCode Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Shareholder Filing, SEC Filing